The Regulation of Clinical Stem Cell Research and Applications: three dynamics of global regulatory diversification (part 3)
In the third and final part of this commentary, Achim Rosemann provides thoughts on abandoning of the multiphase trial system and his concluding remarks.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.